According to the World Health Organization, malocclusion type III is third, most important oral health problem. It may be the least prevalent malocclusion, but it is the most noticeable and challenging for orthodontic therapy. With this narrative review, we wanted to give a summation of the most current knowledge about diagnostics, different therapy options, limitations, and additional factors that can influence the therapy of class III malocclusion to help clinicians and researchers focus on the specific approaches. Therapy options were divided into the following groups: orthopedic, orthodontic, and surgical. The SNA, SNB, and ANB angles (cephalometric values) are the best ones to examine improvements in different skeletal improvements, while dentoalveolar improvements were also described, emphasizing the limitation of orthopedic therapy to change the skeletal discrepancy. Eruption-guided appliances and chin cups are more effective in early childhood, mixed dentition, during permanent teeth eruption, with no significant skeletal discrepancy. If a discrepancy exists, a face mask is the first therapy choice. The therapy of an underdeveloped maxilla can be solved with different palate expanders. Bulkiness, lack of long-term results, and duration of therapy make fixed orthodontic appliances with braces and elastic traction favorable nowadays. If the skeletal discrepancy is major, a surgical approach should be considered. One of the main limitations in articles is the combination of different therapy approaches, ages, and dentition preferred for device application, duration of therapy, and lack of information about long-term outcomes. On the other hand, the lack of original articles is noticeable, so further research should be done.

Background/Aim. The COronaVIrus Disease 2019 (COVID-19) primarily affects the respiratory system, so radiological diagnosis has been shown to be necessary. Chest computed tomography (CT) is to be shown the best modality in suspected COVID-19 cases for initial evaluation because CT findings may be present before the onset of symptoms. The purpose of this study is to show different CT imaging features or patterns in COVID-19 patients with a different time course and disease severity. Methods. This is a prospective cohort study that analysed 330 patients (the average age was 52.37±15.36) with confirmed COVID-19 via laboratory testing. During hospitalization, all patients included in the study underwent chest CT in order to assess the extent of changes in their lungs. Because chest CT images could show different imaging features or patterns in COVID-19 patients with a different time course and disease severity, we classified them into four categories: lung, bronchial, pleural and mediastinal changes. Based on the time interval between the onset of symptoms and the CT scan, all patients were divided into three groups: group 1 (CT scans done ≤1 week after symptom onset); group 2 (CT scans done >1 to 2 weeks after symptom onset); group 3 (CT scans done >2 weeks after symptom onset). In order to more accurately monitor the distribution of changes in the lungs, bilateral lungs were divided into 12 ‘lung’ zones. Each zone was assigned a CT score. ‘Total severity score‘ was calculated by summing the scores for each zone. Results. In 93.6% patients with COVID-19 the CT findings were positive. About 92.1% patients had multiple lesions. The lesions were bilateral in 87.6% of patients, had both peripheral and centrally localised lesions in 63.3% of patients, and occurred more frequently in posterior areas (93%), as well as in lower lung zones (91.2%). The average ‘Total severity score’ was 11.00 (7.00-16.00). The most common CT findings in all patients are the ground- glass opacities (97.7%), reticular pattern (91.3%), consolidation (71.5%) and fibrotic streaks (63.8%). When the time interval is monitored between onset of symptoms and the CT scan, it is noticed that in group 1 changes on CT were found in 80.0% of patients, in group 2 in 95.0%, and in group 3 in 99.4%. Conclusion. CT has proven to be a very important diagnostic method in COVID-19 patients, and together with clinical and laboratory findings, gives a complete picture of the patient's condition and significantly contributes to decision- making for further treatment.

Introduction/Objective. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection manifests with an unpredictable clinical course that could rapidly progress, leading to serious and often fatal complications. The identification of effective laboratory biomarkers that could stratify patients at risk of developing severe forms of the disease is imperative to ensure they receive prompt medical treatment. The aim of our study was to compare baricitinib and tocilizumab regarding clinical outcomes in hospitalized patients with severe COVID-19. Methods. A retrospective study included analysis of data from 82 patients of both sexes who were treated with biological immunosuppressive therapy at the Military COVID Hospital, Karaburma. All patients who met the criteria for use according to the guidelines of the national protocol for the treatment of COVID-19, version XIII, had a consultative decision made for the application of biological immunosuppressive therapy. Half were treated with tocilizumab, and the other half with baricitinib. Results. The results of our study show that the mortality rate is lower in the group treated with tocilizumab compared with the group treated with baricitinib: 17.1% vs. 26.8%, but without statistical significance (p = 0.286). Additionally, the use of tocilizumab reduces the need for mechanical ventilation compared with baricitinib: 53.6% vs. 68.3%, without statistical significance (p = 0.454). Conclusion. The results obtained in our study indicate that both drugs are equally clinically effective.

The long non-coding RNA (lncRNA) GAS5 can be a marker for early diagnosis and postoperative follow-up in the patients with prostate cancer, whereby lower levels of GAS5 correlate with tumorigenesis and unfavourable clinical course. Expression of the GAS5 can be affected by rs145204276 polymorphism, a 5 base pairs insertion-deletion polymorphism shown as ?AGGCA/-?. The aim of this study was to analyse the association between rs145204276 and prostate cancer susceptibility and prognosis. This study was included 121 healthy subjects and 70 patients with prostate cancer. Diagnosis of prostate cancer was established by histopathology after the surgery. Genotyping was performed by allelic discrimination method using the TaqMan? assay. In the healthy subjects, the obtained frequencies of GAS5 rs145204276 genotypes were 80.2% of ins/ins, 16.5% of ins/del and 3.3% of del/del. The allele frequencies were 88.5% of ins and 11.5% of del, respectively. In the patient group, the frequencies of ins/ins, ins/del and del/del genotypes were 70%, 20% and 10%, respectively; the frequency of ins allele was 80% and the frequency of del allele was 20%. Observed frequencies of GAS5 rs145204276 genotypes were not significantly different between healthy subjects and patients with prostate cancer, and also between prognostic groups of prostate cancer. This study demonstrate no significant association between GAS5 rs145204276 and sussceptibility/prognosis of prostate cancer.

Background/Aim. About 1.8 million new lung cancer cases are diagnosed worldwide every year, and about 1.6 million cases have a fatal outcome. Despite improvements in treatment in the previous decades, the survival of patients with lung cancer is still poor. The five-year survival rate is about 50% for patients with localized disease, 20% for patients with regionally advanced disease, 2% for patients with metastatic disease, and about 14% for all stages. The median survival of patients with untreated non-small cell lung carcinoma (NSCLC) in the advanced stage is four to five months, and the annual survival rate is only 10%. The aim of the study was to determine the results of treatment with concomitant chemoradiotherapy (CHRT) in terms of efficacy and toxicity in selected patients with advanced inoperable NSCLC. Methods. The study included data analysis of 31 patients of both sexes who were diagnosed and histopathologically verified with NSCLC in inoperable stage III and were referred by the Council for Malignant Lung Diseases to the Radiotherapy Department of the Military Medical Academy in Belgrade, Serbia for concomitant CHRT treatment. Upon expiry of the three months from the performed radiation treatment (RT), the tumor resonance was assessed based on multislice computed tomography (MSCT) examination of the chest and upper abdomen according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. According to the same criteria, progression-free survival (PFS), as well as overall survival (OS), was assessed every three months during the first two years, then every 6 months or until the onset of disease symptoms. Results. The median PFS was 13 months, and the median OS was 20 months. During and immediately after RT, 9 (29%) patients had a grade 2 or higher adverse events. Conclusion. The use of concomitant CHRT in patients in the third stage of locally advanced inoperable NSCLC provides a good opportunity for a favorable therapeutic outcome with an acceptable degree of acute and late toxicity and represents the standard therapeutic approach for selected patients in this stage of the disease.